<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prevention of tuberculosis: BCG immunization and nutritional supplementation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prevention of tuberculosis: BCG immunization and nutritional supplementation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prevention of tuberculosis: BCG immunization and nutritional supplementation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">C Fordham von Reyn, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Bernardo, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Tools for prevention of tuberculosis (TB) include:</p><p class="bulletIndent1"><span class="glyph">●</span>BCG immunization</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nutritional supplementation </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection control </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Screening and treatment of TB infection (latent TB) </p><p></p><p>Issues related to BCG immunization and nutritional supplementation for prevention of TB are discussed below. </p><p>Issues related to infection control and TB screening are discussed separately. (See  <a class="medical medical_review" href="/d/html/8000.html" rel="external">"Tuberculosis transmission and control in health care settings"</a> and  <a class="medical medical_review" href="/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a> and  <a class="medical medical_review" href="/d/html/8017.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults without HIV infection"</a> and  <a class="medical medical_review" href="/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"</a> and  <a class="medical medical_review" href="/d/html/8020.html" rel="external">"Tuberculosis infection (latent tuberculosis) in children"</a> and  <a class="medical medical_review" href="/d/html/135001.html" rel="external">"Tuberculosis infection (latent tuberculosis) in pregnancy"</a>.)</p><p class="headingAnchor" id="H1904710678"><span class="h1">TERMINOLOGY</span><span class="headingEndMark"> — </span>TB terminology is inconsistent in the literature [<a href="#rid1">1</a>]. Relevant terms are defined in the table  (<a class="graphic graphic_table graphicRef132526" href="/d/graphic/132526.html" rel="external">table 1</a>)</p><p class="headingAnchor" id="H1994976002"><span class="h1">IMMUNIZATION</span></p><p class="headingAnchor" id="H2"><span class="h2">Mycobacteria and host immunity</span><span class="headingEndMark"> — </span>Virtually any prior mycobacterial infection (whether naturally acquired or vaccine induced) appears to produce some level of protection against subsequent disease due to TB and, in some cases, to other mycobacteria [<a href="#rid2">2</a>]. Natural infections that confer protection against TB include prior contained infection with <em>Mycobacterium tuberculosis</em> itself or prior infection with nontuberculous mycobacteria [<a href="#rid3">3,4</a>]. These observations suggest that protection is conferred by the immune response to common mycobacterial antigens. (See  <a class="medical medical_review" href="/d/html/8026.html" rel="external">"Immunology of tuberculosis"</a>.)</p><p>Prior infection with <em>M. tuberculosis</em> that has been contained provides as much as 80 percent protection against disease after subsequent exposure [<a href="#rid5">5</a>]. However, prior active disease is associated with an increased risk of a second episode of active TB due to a different strain in patients with or without HIV infection [<a href="#rid6">6-12</a>].</p><p>Bacille Calmette-Guérin (BCG) has also been associated with an overall reduction in childhood mortality not attributable to TB; this effect is not fully understood but may be related to epigenetic and metabolic reprogramming of innate immune cells [<a href="#rid13">13</a>].</p><p><a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> is administered either intradermally or percutaneously. Since natural infection and sensitization to <em>M. tuberculosis</em> in humans usually occurs by the respiratory route, research is being conducted on aerosol administration of BCG [<a href="#rid14">14,15</a>].</p><p class="headingAnchor" id="H454607066"><span class="h2">Bacille Calmette-Guérin vaccine</span><span class="headingEndMark"> — </span>Bacille Calmette-Guérin (BCG) is a live strain of <em>Mycobacterium bovis</em> developed by Calmette and Guérin for use as an attenuated vaccine to prevent tuberculosis (TB) and other mycobacterial infections. The vaccine was first administered to humans in 1921 and remains the only vaccine against TB in general use.</p><p><a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> is the most widely administered vaccine in the world; it has been given to over three billion individuals, principally in the setting of routine newborn immunization (as dictated by guidelines of the World Health Organization) [<a href="#rid16">16</a>]. There are multiple BCG vaccines in use around the world, produced by different manufacturers and administered via different schedules.</p><p><a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> is also effective for protection against other mycobacterial infections including leprosy and Buruli ulcer. In addition, it is used as an immunostimulant in the treatment of superficial carcinoma of the bladder. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/16520.html" rel="external">"Leprosy: Treatment and prevention"</a> and  <a class="medical medical_review" href="/d/html/5349.html" rel="external">"Buruli ulcer (Mycobacterium ulcerans infection)"</a> and  <a class="medical medical_review" href="/d/html/2973.html" rel="external">"Infectious complications of intravesical BCG immunotherapy"</a>.)</p><p class="headingAnchor" id="H5714554"><span class="h3">Immune response to BCG</span><span class="headingEndMark"> — </span>Numerous reports have evaluated the immune response to primary Bacille Calmette-Guérin (BCG) immunization. Studies among infants demonstrate BCG-associated induction of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, interferon (IFN)-gamma<sup>+</sup>, interleukin-2<sup>+</sup>, tumor necrosis factor (TNF)-alpha<sup>+</sup>, and polyfunctional CD4<sup>+</sup> T cells [<a href="#rid17">17</a>]. However, none of these responses were found to correlate with protection against TB in BCG-immunized infants [<a href="#rid18">18</a>] nor have any studies identified a surrogate marker of BCG-induced protection against TB. Among BCG-immunized infants in Uganda, lower rates of purified protein derivative (PPD)-specific T cell responses have been found among infants of mothers with TB infection than infants of mothers without TB infection [<a href="#rid19">19</a>]. In contrast, a study from South Africa found no difference in BCG-specific T cell proliferative responses or cytokine/chemokine induction between infants of mothers with and without TB infection [<a href="#rid20">20</a>].</p><p>Infant exposure to maternal HIV does not appear to have a significant effect on infant immune response to BCG administered at birth. In one study, infant immune responses to BCG did not differ between HIV-exposed and HIV-unexposed infants [<a href="#rid20">20</a>]. In another study, responses to <em>M. tuberculosis</em> PPD were marginally lower at 14 weeks in the HIV-exposed group but responses to BCG were similar; all measured responses were similar at 24 and 52 weeks [<a href="#rid21">21</a>]. However, actual infant infection with HIV is a contraindication to BCG immunization (see below). </p><p>Studies in adults indicate that BCG induces CD4<sup>+</sup>, IFN-gamma responses, and IFN-gamma and TNF-alpha secreting CD8<sup>+</sup> cells with cytotoxic activity; data on polyfunctional T cells have been conflicting [<a href="#rid22">22</a>]. In a study among BCG-naïve, interferon-gamma release assay-negative adults from the Netherlands, immune responses could be separated into two distinct patterns: a predominant proinflammatory response and a predominant T regulatory cell response with no cytokine induction [<a href="#rid22">22</a>]. An increasing body of literature is exploring the potential role that BCG-induced humoral immunity may play a role in protection against TB disease [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H1056054773"><span class="h3">Timing of infant immunization</span><span class="headingEndMark"> — </span>Several studies have assessed immune responses among infants whose BCG immunization was delayed for several weeks after birth. In one study in South Africa, HIV-unexposed infants immunized at eight weeks of age had higher frequencies of BCG-specific polyfunctional T cells at one year of age compared with infants immunized at birth [<a href="#rid24">24</a>]. In another study among HIV-unexposed infants in the Gambia, cytokine responses were lower among infants immunized at 18 weeks of age than among infants immunized at birth; however, immune responses in the two groups were comparable at 36 weeks [<a href="#rid25">25</a>]. In a study among HIV-exposed infants in South Africa, immune responses were compared in infants immunized at birth versus eight weeks; at six weeks following immunization, BCG-specific T cell responses were similar, but at 14 weeks the frequency of IFN-gamma expressing CD4<sup>+</sup> T cells and multifunctional BCG-specific responses were higher in the delayed immunization arm [<a href="#rid26">26</a>].</p><p>These immunologic studies of delayed infant BCG immunization cannot yet be applied to immunization policy since a surrogate immune marker of BCG-induced protection has not been identified [<a href="#rid27">27</a>]. Routine immunization at birth remains the preferred practice since delayed immunization may reduce BCG compliance rates and subject infants to an increased risk of interim TB exposure and all-cause mortality [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H1480962069"><span class="h3">BCG vaccine efficacy</span><span class="headingEndMark"> — </span>The efficacy of BCG varies depending on whether it is administered as a primary or booster vaccine, and whether the endpoint of interest is TB infection or TB disease. These categories are considered separately below.</p><p class="headingAnchor" id="H2930297665"><span class="h4">Efficacy against TB infection</span></p><p class="headingAnchor" id="H1155568853"><span class="h5">Primary immunization</span><span class="headingEndMark"> — </span>Most studies of BCG have evaluated the efficacy for protection against TB disease. In older BCG trials, TB infection was not used as an efficacy endpoint since the presence of TB infection could only be assessed using the <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> [TST], which itself is affected by BCG. (See  <a class="medical medical_review" href="/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a>.)</p><p>Interferon-gamma release assays (IGRAs) have been shown to be useful tools for evaluating the efficacy of BCG in preventing TB infection [<a href="#rid29">29-35</a>] (see  <a class="medical medical_review" href="/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In one systematic review and meta-analysis including 14 studies and more than 3800 individuals who received BCG vaccination, BCG had an overall protective efficacy of 19 percent (risk ratio [RR] 0.81, 95% CI 0.71-0.92) [<a href="#rid32">32</a>]. In a restricted analysis of studies in which BCG was administered at birth, protective efficacy of 28 percent (RR 0.72, 95% CI 0.56-0.93) was observed. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study from Greenland including nearly 1700 participants, BCG was associated with reduced risk of TB infection (hazard ratio [HR] 0.52) and risk of TB disease (HR 0.50); these effects persisted beyond 15 years of age [<a href="#rid33">33</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a cross-sectional analysis of a cohort including more than 3400 TB contacts in the United Kingdom, a strong association was found between BCG immunization and protection against TB infection. The overall vaccine efficacy was 30 percent and diminished with time since immunization; however, the prevalence of TB infection at &gt;20 years was still lower among those with prior BCG immunization [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a household contact study from Indonesia, BCG immunization was associated with protection against both baseline TB infection (positive IGRA) and incident TB infection (conversion from negative baseline IGRA to positive IGRA at 14 weeks). Protection was strongest against incident infection (relative risk 0.56, 95% CI 0.40-0.77) and decreased with increasing age [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An observational study among 1404 children and adolescents immigrating to Sweden showed that a BCG scar was associated with a 59 percent reduced risk of TB infection, as documented by a positive TST or IGRA [<a href="#rid36">36</a>].</p><p></p><p class="headingAnchor" id="H1860545689"><span class="h5">Booster immunization</span><span class="headingEndMark"> — </span>In a randomized trial more than 900 IGRA-negative adolescents in South Africa who received neonatal BCG vaccination were randomized to receive BCG booster, the H4:IC31 vaccine (an investigational vaccine containing mycobacterial antigens), or placebo [<a href="#rid37">37</a>]. Neither vaccine was effective in preventing initial IGRA conversion to positive. However, the rate of sustained IGRA conversion (a potential surrogate for TB infection defined as conversion to positive IGRA without reversion to negative IGRA at six months following vaccination) was reduced among recipients of the <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> by 45.4 percent and among recipients of the H4:IC131 vaccine by 30.5 percent. </p><p class="headingAnchor" id="H4"><span class="h4">Efficacy against TB disease</span></p><p class="headingAnchor" id="H3536141808"><span class="h5">Primary immunization</span><span class="headingEndMark"> — </span>BCG is administered routinely at birth in TB-endemic countries as a component of the global Essential Program on Immunization (EPI). Because efficacy in mycobacteria-naïve newborns is higher than in older children and adults, these groups are considered separately here. BCG is 70 to 80 percent effective against all forms of TB when administered at birth to mycobacteria-naïve infants [<a href="#rid38">38</a>]. Primary vaccination of older children and adults is considerably less effective [<a href="#rid39">39-41</a>]. These differences are likely due to the immune status of the recipient and degree of prior exposure to mycobacteria (both <em>M. tuberculosis</em> and nontuberculous mycobacteria [NTM]).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycobacteria-naïve infants and newborns</strong> - The efficacy of BCG immunization in providing protection against subsequent TB in mycobacteria-naïve newborns and infants has been evaluated in four prospective trials conducted before effective treatment of TB was available [<a href="#rid42">42-47</a>]. Collectively, these trials demonstrated an efficacy of 73 percent for protection against active disease and 87 percent against death [<a href="#rid42">42</a>]. Infant BCG immunization is also very effective in preventing tuberculous meningitis and disseminated disease in children (75 to 86 percent efficacy) [<a href="#rid38">38-42,48,49</a>]. Infant BCG immunization provides long-term protection against pulmonary TB. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a 40-year population-based survey from Norway, childhood BCG immunization provided 67 percent protection against pulmonary TB at 10 years and 63 percent protection at 20 years [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a cohort study from Greenland, infant BCG immunization provided 50 percent protection against TB disease in older children and adults, the age groups where most disease is pulmonary [<a href="#rid33">33</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other studies have documented significant efficacy for least 15 years, although efficacy typically begins to wane after this interval [<a href="#rid50">50,51</a>]. Waning BCG-induced protection has led to studies of BCG boosters and to studies of investigational TB vaccine boosters. (See <a class="local">'Booster immunization'</a> below and <a class="local">'TB vaccines under development'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycobacteria-exposed older children and adults</strong> - The protective efficacy of primary BCG immunization appears to decrease as prior exposure to mycobacteria increases, which in turn is a function of age and rates of endemic TB [<a href="#rid38">38,52</a>]. Thus, BCG is less effective when primary immunization is provided to older individuals than when it is provided to mycobacteria-naïve newborns [<a href="#rid53">53</a>]. Two factors may be relevant: first, natural mycobacterial infection may provide protection equal to BCG ("masking") and second, BCG may have reduced replication (and therefore reduced efficacy) in the face of prior mycobacterial immunity ("blocking") [<a href="#rid2">2,54</a>]. The second hypothesis is supported by an animal model in which prior infection with NTM blocks the protective effects of BCG [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Analyses that have combined trial results in newborns with trial results in older children and adults have led to the misleading conclusion that the efficacy of BCG is "variable." As noted above, BCG has been uniformly effective in all prospective trials conducted among mycobacteria-naïve infants. Variable efficacy has also been incorrectly attributed to higher rates of NTM infection in trials conducted near the equator, most notably based on the results of a trial in South India with methodologic flaws. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The South India 1980 trial was a large randomized trial designed to investigate the efficacy of BCG against TB disease [<a href="#rid56">56,57</a>]. The study objectives of this trial were: (1) to compare the efficacy of different BCG strains and doses and (2) to assess the efficacy of BCG in individuals with and without prior latent TB (determined by TST).</p><p></p><p class="bulletIndent2">In reality, however, the trial was largely a study of the effect of primary BCG immunization in older children and adults, many of whom were already tuberculin positive and all of whom lived in an area where prior infection with <em>Mycobacterium leprae</em> was prevalent. Over 270,000 patients were enrolled, but only 0.6 percent were mycobacteria-naïve newborns. Surveillance for TB was based on positive chest radiographs, which were only performed at age ≥5 years; those with positive radiographs had sputum microbiology. Criteria for TB were limited to positive sputum culture or positive acid-fast bacilli stain, and there were no methods for detecting extrapulmonary TB. These methods would be insensitive for the diagnosis of TB in children. Further, the observed rate of TB in this large study cohort was half the predicted rate. </p><p></p><p class="bulletIndent2">A critical review of BCG trial methodology concluded that this trial had major methodologic flaws [<a href="#rid40">40</a>]. At most, this trial demonstrated that BCG vaccination of mycobacteria-experienced older children and adults in India does not lead to a reduction in pulmonary TB defined by positive sputum cultures and chest radiographs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An individual participant data meta-analysis examined 26 cohort studies of tuberculosis contacts from 17 countries where BCG was given at birth, published between January 1, 1998, and April 7, 2018 [<a href="#rid58">58</a>]. Of 68,552 contacts, 1782 (2.6 percent) overall developed tuberculosis: 1309 (2.6 percent) of 49,686 BCG-vaccinated at birth subjects versus 473 (2.5 percent) of 18,866 unvaccinated subjects. The overall effectiveness of BCG vaccination was 18 percent (adjusted odds ratio [OR] 0.82, 95% CI 0.74-0.91). When stratified by age, BCG vaccination significantly protected against tuberculosis only in children younger than five years of age (adjusted OR 0.63, 95% CI 0.49-0.81). Among older children, adolescents, and adults, prior BCG vaccination provided no protection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BCG efficacy does not correlate with latitude or higher baseline rates of exposure to NTMs near the equator, as suggested previously [<a href="#rid59">59</a>]. Studies indicate that population exposure to NTMs is high in northern as well as southern latitudes [<a href="#rid38">38,60</a>]. Further, no well-designed prospective trials among mycobacteria-naïve infants (the population in which BCG is most effective) have been conducted in southern latitudes. When identical methods were applied to surveillance for disseminated NTM infection in patients with AIDS, rates were high in the northern hemisphere and low in the southern hemisphere: 11 to 22 percent in the United States and Finland versus 2 to 3 percent in Kenya and Trinidad [<a href="#rid61">61</a>]. This disparity may be related to protection associated with the higher rate of TB in southern regions. A United States study showed that prior TB was associated with a reduced risk of disseminated <em>Mycobacterium</em> <em>avium</em> in patients with AIDS [<a href="#rid62">62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mycobacteria-naïve older children and adults</strong> - Some older children and adults remain sufficiently mycobacteria naïve to respond to BCG. Trials in which TSTs were used to exclude children or adults with prior mycobacterial immunity have been able to demonstrate efficacy against TB disease in some cases.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial initiated in the 1950s that involved over 25,000 TST-negative British teenage students demonstrated <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> efficacy of 76 percent against TB disease at 15 years [<a href="#rid49">49</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A randomized trial of BCG vaccination was conducted between 1935 and 1938 among 3287 TST-negative Native Americans age 0 to 20 (28 percent ≤5 years). Evaluation of vaccine recipients 11 years after vaccine administration demonstrated 75 percent reduction in radiographically diagnosed TB; evaluation at 20 years demonstrated an 82 percent reduction in overall mortality due to TB. The protective efficacy of BCG against disease due to TB was 70 percent. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Evaluation of vaccine recipients 60 years after vaccine administration (the longest follow-up period of any BCG trial) included data for 1998 of the original participants and demonstrated protection against pulmonary TB was 52 percent at 50 years [<a href="#rid48">48</a>]. </p><p></p><p class="bulletIndent2">This trial also demonstrated that BCG may confer protection against multiple episodes of TB. The rate of two or more episodes of TB was 34 per 100,000 person-years in the placebo group and 4 per 100,000 person-years in the BCG group, consistent with a vaccine efficacy of 89 percent (95% CI 53-99 percent) [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a subsequent analysis of the South India trial, BCG was found to be 32 percent effective in subjects who had negative NTM skin test results (PPD from <em>Mycobacterium intracellulare </em>[PPD-B]) at baseline [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a study from Brazil, where approximately 70 percent of children are tuberculin negative, BCG efficacy was 25 percent in subjects who received their first <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> at age 7 to 14 [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Efficacy does not appear to be related to the particular BCG strain used in the vaccine or to latitude [<a href="#rid59">59</a>]</p><p></p><p class="headingAnchor" id="H1088806841"><span class="h5">Booster immunization</span><span class="headingEndMark"> — </span>Waning immunity 15 to 20 years after primary BCG vaccination in infancy has been the rationale for efforts to develop an effective booster for adolescents and adults [<a href="#rid38">38</a>]. BCG revaccination is generally well tolerated and carries minimal risk [<a href="#rid65">65</a>]. However, large studies in Malawi and Brazil have shown that a booster dose of live BCG does not increase the efficacy of protection against TB disease [<a href="#rid52">52,66,67</a>]. A follow-up study indicated that revaccination also had no demonstrable effect on long-term mortality [<a href="#rid68">68</a>]. The host immune response induced by the initial BCG dose may prevent replication of live organisms administered in a subsequent vaccine dose ("blocking") [<a href="#rid55">55</a>] or the acquisition of infections due to nontuberculous mycobacteria after infancy may provide protection equivalent to a BCG booster ("masking").</p><p class="headingAnchor" id="H3773102338"><span class="h4">Efficacy against other mycobacterial infections</span><span class="headingEndMark"> — </span>Protection against mycobacterial disease does not appear to be species-specific; BCG may confer protection against infections due to nontuberculous mycobacteria [<a href="#rid69">69</a>]. Further, NTM infection is associated with protection against TB [<a href="#rid70">70</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycobacterium leprae</em> – Studies have demonstrated that BCG reduces the risk of disease due to <em>M. leprae</em> by 50 to 80 percent, and this effect may be increased with booster doses of BCG [<a href="#rid66">66,71</a>]. (See  <a class="medical medical_review" href="/d/html/16520.html" rel="external">"Leprosy: Treatment and prevention", section on 'Prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycobacterium ulcerans</em> – BCG immunization of infants induces <em>M. ulcerans</em>-specific immune responses [<a href="#rid72">72</a>]. Some data suggest BCG confers some protection preventing Buruli ulcer disease due to <em>M. ulcerans </em>[<a href="#rid73">73,74</a>] and BCG may reduce the risk of osteomyelitis, a major complication of <em>M. ulcerans</em> infection [<a href="#rid75">75</a>]. However, other retrospective data have found no evidence for BCG protection against Buruli ulcer disease [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/d/html/5349.html" rel="external">"Buruli ulcer (Mycobacterium ulcerans infection)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>M. avium complex</em> – BCG provides cross protection against childhood lymphadenitis due to <em>M. avium</em> complex [<a href="#rid77">77</a>]. Cessation of routine childhood BCG immunization in Sweden and Finland was associated with a marked increase in the rate of childhood adenitis due to NTM [<a href="#rid78">78,79</a>]. (See  <a class="medical medical_review" href="/d/html/85894.html" rel="external">"Nontuberculous mycobacterial pulmonary infections in children", section on 'M. avium complex'</a>.)</p><p></p><p class="headingAnchor" id="H11026971"><span class="h4">Effect on child morbidity and mortality</span><span class="headingEndMark"> — </span>Neonatal BCG administration provides protection against TB and reduces all-cause mortality among neonates and infants. In Guinea-Bissau, BCG reduced all-cause neonatal mortality by &gt;40 percent among low birthweight infants [<a href="#rid80">80</a>]. Protection against septicemia and respiratory infection has also been observed [<a href="#rid81">81</a>]. In a randomized controlled trial in Guinea-Bissau, infants &lt;2500 g who received BCG at birth had a 43 percent reduction in 28-day infectious disease mortality compared with infants with delayed administration of BCG [<a href="#rid82">82</a>]. A randomized trial comparing early (pre-1931) and later strains of BCG-based vaccines showed that effects on childhood morbidity did not differ between "early" (BCG Russia) and "late" (BCG Japan/BCG Denmark) BCG strains [<a href="#rid83">83</a>]. </p><p>Another study in Guinea-Bissau (where as many as 50 percent of BCG-immunized children do not develop an associated scar) noted that development of a BCG scar was associated with lower mortality and morbidity among children &lt;5 years of age. Protection was strongest against respiratory infection and in the first year of life [<a href="#rid84">84</a>].</p><p>Additional analysis of data from randomized trials in Guinea-Bissau has shown that the beneficial effect of BCG at birth on neonatal mortality in low-birth weight infants is maximal during days 1 to 7 of life among boys and during days 8 to 28 among girls [<a href="#rid85">85</a>]. In one meta-analysis evaluating BCG administration to low birth weight or premature infants when immunization was given early (≤7 days) or later (&gt;7 days), the safety and immunogenic profiles were similar [<a href="#rid86">86</a>]. In addition, a modeling study of infant BCG immunization found that universal immunization at birth (rather than six weeks or later) could reduce global pediatric TB mortality by 16.5 percent [<a href="#rid28">28</a>].</p><p>A study from Uganda has demonstrated that BCG immunization on the first day of life reduces neonatal infectious disease morbidity compared with immunization at six weeks and suggests that the benefits documented in Guinea-Bissau may be seen in other regions where neonatal infectious diseases are common. The study documented a 25 percent reduction in episodes of clinician-diagnosed infectious disease in the first six weeks of life. Effects were more pronounced in low-birthweight babies (≤2500 g versus &gt;2500 g) and in boys (versus girls) [<a href="#rid87">87</a>].</p><p>These findings emphasize the importance of administering BCG at birth rather than at later follow-up health visits, and that a multiple-dose BCG vial should be opened even if it will only be used to administer a single dose of BCG to a newborn.</p><p class="headingAnchor" id="H1773121452"><span class="h4">Effect on risk of respiratory infection and COVID-19 in adults</span><span class="headingEndMark"> — </span>It has been hypothesized that the immunomodulatory properties of <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> might enhance protection against coronavirus disease 2019 (COVID-19). </p><p>In areas where most individuals receive BCG at birth, clinical trials include:</p><p class="bulletIndent1"><span class="glyph">●</span>A 2023 trial including more than 3300 health care workers in Australia, Europe, and Brazil who were randomly assigned to receive BCG-Denmark vaccine or placebo; BCG vaccination did not reduce the risk of COVID-19 infection after 12 months of follow-up [<a href="#rid88">88</a>]. The hazard ratio for any COVID-19 episode in the BCG group as compared with the placebo group was 1.23 (95% CI 0.96-1.59). The risk of symptomatic COVID-19 by six months in the BCG and placebo groups was 14.7 and 12.3 percent, respectively (risk difference, 2.4 percentage points; 95% CI -0.7 to 5.5). The development of COVID-19-specific vaccines sooner than expected was as an important limitation for this trial, leading to smaller sample size and shortened observation time. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2022 trial including 1000 healthcare workers in South Africa randomly assigned to receive with BCG or placebo; no benefit was observed after one year of follow-up [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2020 trial including 200 hospitalized adults in Greece randomly assigned to receive BCG or placebo on the day of discharge; new infections (predominantly respiratory infections) occurred less frequently among those who received BCG (25 versus 42 percent) [<a href="#rid90">90</a>].</p><p></p><p>In a 2022 trial including 144 BCG-naïve patients in the United States randomly assigned to receive BCG (three doses of BCG over 15 months) or placebo, COVID-19 infection occurred less frequently among those who received BCG (1 versus 12.5 percent) [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H2971311609"><span class="h4">Effect on risk of malignancy</span><span class="headingEndMark"> — </span>Studies have been conflicting on whether BCG vaccination in childhood might have an association with later development of leukemia or lymphoma.<strong> </strong>Some studies have suggested that BCG vaccination might be associated with increased incidence of and mortality due to leukemia and lymphoma, especially non-Hodgkin lymphoma [<a href="#rid92">92-94</a>], while others have suggested no difference or decreased leukemia incidence and mortality [<a href="#rid95">95-97</a>].</p><p>A published retrospective, 60-year follow-up of a multicenter clinical trial of BCG vaccination in American Indian and Native Alaskans in the United States, reported that BCG vaccination in childhood was associated with a significant reduction in lung cancer. In this study, 2963 subjects, median age 8 years, were randomized to receive a single dose of BCG (strain 317 or 575) or placebo. While there was no difference in overall mortality or cancer diagnosis between groups, including lymphoma or leukemia, the rate of lung cancer was significantly lower in BCG vaccinated recipients (18.2 versus 45.4 cases per 100,000 person-years; hazard ratio 0.38, 95% CI 0.20-0.74), controlling for sex, region, alcohol overuse, smoking, and TB. The mechanism of this observed protection is unknown [<a href="#rid98">98</a>].</p><p class="headingAnchor" id="H9"><span class="h4">Areas of uncertainty</span><span class="headingEndMark"> — </span>The efficacy of BCG vaccination has not been studied in the setting of drug-resistant TB; however, drug susceptibility would not be expected to influence the efficacy of BCG. There are no prospective data on the efficacy of BCG for health care workers or travelers. (See <a class="local">'Groups to consider for BCG vaccination'</a> below.)</p><p class="headingAnchor" id="H12"><span class="h3">Safety and adverse effects</span></p><p class="headingAnchor" id="H2139135198"><span class="h4">General principles</span><span class="headingEndMark"> — </span>Injection site reactions following BCG vaccination are common. More serious adverse effects include osteitis, osteomyelitis, and disseminated infection. Potential factors affecting the rate of adverse reactions include the BCG dose, vaccine strain, and method of vaccine administration.</p><p>As many as 95 percent of BCG recipients have a local reaction at the site of injection characterized by a bluish-red pustule accompanied by pain, swelling, and erythema within two to three weeks after vaccination. Ulceration with drainage occurs at the vaccine site in about 70 percent of cases, and about 75 percent of recipients experience myalgia. After about six weeks, the pustule ulcerates, forming a lesion approximately 5 mm in diameter. Lesions typically heal by three months with permanent identifiable scar in approximately 80 percent of recipients  (<a class="graphic graphic_picture graphicRef91059" href="/d/graphic/91059.html" rel="external">picture 1</a>).</p><p>Less common manifestations include abscess and regional lymphadenitis (1 to 2 percent). These may be accompanied by draining sinus tracts or fistulae; the risk for neonates is higher than for older children [<a href="#rid99">99,100</a>].</p><p>Management of local reactions consists of attentive wound care. Since viable organisms can be recovered from ulcer drainage, vaccination sites should be covered to reduce transmission of the vaccine strain [<a href="#rid101">101</a>]. Abscess or fistula formation may rarely require surgical drainage. In the setting of suppurative lymphadenitis, some favor antimycobacterial therapy, although antimicrobial therapy has not been shown to be beneficial in meta-analyses [<a href="#rid102">102-105</a>]. Nonsuppurative lesions are best managed with observation alone [<a href="#rid102">102,103</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Osteitis and osteomyelitis</strong> – BCG osteitis and osteomyelitis are rare; these entities may occur as a result of direct spread from the administration site; less commonly, these may also occur as a result of dissemination [<a href="#rid106">106</a>]. Osteitis affecting the epiphyses of the long bones (particularly the leg) can occur 4 to 24 months after vaccination. It has been reported in 0.01 per million vaccinees in Japan (multipuncture technique) and 30 per million in Finland (intradermal technique) [<a href="#rid100">100</a>]. There is an increased incidence of genetic variants in the gene encoding Toll-like receptor 2 among infants who develop BCG osteitis following vaccination, compared with those that do not [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/d/html/3985.html" rel="external">"Toll-like receptors: Roles in disease and therapy", section on 'Specific TLRs'</a>.)</p><p></p><p class="bulletIndent1">Treatment of osteomyelitis usually consists of surgical debridement plus administration of <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> (INH) and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (RIF) for 6 to 12 months [<a href="#rid100">100,108</a>] (BCG is resistant to <a class="drug drug_general" data-topicid="9836" href="/d/drug information/9836.html" rel="external">pyrazinamide</a> and, unlike treatment of wild strain <em>M. bovis</em> infection, <a class="drug drug_general" data-topicid="9430" href="/d/drug information/9430.html" rel="external">ethambutol</a> is not generally needed). (See  <a class="medical medical_review" href="/d/html/8006.html" rel="external">"Mycobacterium bovis"</a> and  <a class="medical medical_review" href="/d/html/2973.html" rel="external">"Infectious complications of intravesical BCG immunotherapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disseminated disease</strong> – Disseminated disease following BCG vaccination occurs most commonly in the setting of immunosuppression. Populations at risk for dissemination include infants with severe combined immunodeficiency, individuals with HIV infection or other immunodeficiency, and individuals who have received <a class="drug drug_general" data-topicid="102734" href="/d/drug information/102734.html" rel="external">intravesical BCG</a> for bladder cancer [<a href="#rid109">109</a>]. The risk of disseminated BCG in infants with HIV infection ranges from 403 to 1300 per 100,000 doses administered. Mortality among children with HIV infection and disseminated BCG is about 75 percent, although this figure is from studies in which most children were not on current antiretroviral therapy (ART) [<a href="#rid110">110-112</a>]. In the pre-HIV era, the rate of disseminated BCG was reported to be between 0.19 and 1.56 per million vaccinees [<a href="#rid110">110</a>].</p><p></p><p class="bulletIndent1">Although most cases of disseminated BCG have been reported in the weeks and months following childhood immunization, case reports suggest that reactivation can occur years later in the setting of immunosuppression [<a href="#rid110">110</a>]. Clinical manifestations and treatment of disseminated disease due to BCG are outlined separately. (See  <a class="medical medical_review" href="/d/html/2973.html" rel="external">"Infectious complications of intravesical BCG immunotherapy", section on 'Systemic complications'</a> and  <a class="medical medical_review" href="/d/html/8006.html" rel="external">"Mycobacterium bovis", section on 'Treatment'</a>.)</p><p></p><p class="headingAnchor" id="H311230788"><span class="h4">HIV infection</span><span class="headingEndMark"> — </span>Safety of BCG administration in patients with HIV infection is an important concern given that it is a live vaccine. Adverse effects due to BCG vaccination may be more frequent among persons who have advanced or symptomatic HIV infection than among persons who have asymptomatic HIV infection, are on effective ART, or are not HIV infected [<a href="#rid113">113-117</a>].</p><p>Case reports of BCG-related lymphadenitis, local ulceration, and disseminated BCG disease (which can occur several years after BCG vaccination) have been described in patients with HIV infection. In a retrospective study of 352 children with HIV infection started on ART, clinically significant complications of BCG immunization were observed in 6 percent of cases [<a href="#rid118">118</a>]. In some cases, these reactions appeared to be due to immune reconstitution inflammatory syndrome [<a href="#rid112">112,118,119</a>]. (See <a class="local">'Safety and adverse effects'</a> above and  <a class="medical medical_review" href="/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H28008830"><span class="h4">Management of disseminated BCG</span><span class="headingEndMark"> — </span>Patients with disseminated BCG infection should be treated with INH and RIF for at least several months. In the setting of immunosuppression, addition of <a class="drug drug_general" data-topicid="9438" href="/d/drug information/9438.html" rel="external">ethionamide</a> may be beneficial. This was illustrated in a small series of children with HIV infection and BCG-induced complications for whom treatment with INH, RIF, and ethionamide was administered [<a href="#rid118">118</a>]. Patients with HIV infection and disseminated BCG who are not already on combination ART should be started on ART. Vaccine-strain BCG is sensitive to INH and RIF; however, some suggest that resistance to INH or RIF may develop in children with HIV infection treated for complications of BCG [<a href="#rid120">120,121</a>].</p><p>Issues related to systemic BCG are discussed further separately. (See  <a class="medical medical_review" href="/d/html/2973.html" rel="external">"Infectious complications of intravesical BCG immunotherapy", section on 'Systemic complications'</a>.)</p><p class="headingAnchor" id="H995623805"><span class="h3">Administration and dosing</span><span class="headingEndMark"> — </span>There is no evidence that one strain of BCG is preferable or superior to another. Numerous strains of BCG have been used to produce a <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a>, and none of these strains is demonstrably superior in terms of their efficacy or immunogenicity. In the United States, BCG for prevention of TB is manufactured by Merck as the Tice strain [<a href="#rid122">122</a>] but is often difficult to obtain. Intravesical forms of BCG are available for treatment of bladder cancer but not for prevention of TB</p><p>BCG can be administered intradermally or by multiple percutaneous puncture using a device with multiple tines. The clinical efficacy of intradermal and percutaneous administration appears comparable; this was illustrated in a study of 11,680 newborn infants in South Africa randomized to receive intradermal or percutaneous BCG; the rate of TB was equivalent between the groups in the first two years of life [<a href="#rid123">123</a>].</p><p>The World Health Organization (WHO) favors intradermal administration of BCG. Percutaneous puncture is the method recommended by the manufacturer for BCG distributed in the United States; we favor intradermal administration where available for ease of administration and standardization of dose [<a href="#rid123">123</a>]. Intradermal administration appears to result in greater in vitro immunogenicity, skin test conversion, and scarring than percutaneous administration [<a href="#rid124">124</a>].</p><p>BCG is supplied as a lyophilized product and must be reconstituted according to product specific instructions (different dilutions for adults and infants). The standard volume for intradermal administration of <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> for adults after reconstitution is 0.1 mL. The standard volume for multiple puncture administration is 0.2 to 0.3 mL. The dose for infants and neonates up to 12 months of age is 0.05 mL for intradermal administration or 0.2 to 0.3 mL for multiple puncture administration. Other childhood vaccines can be administered simultaneously with BCG.</p><p class="headingAnchor" id="H15"><span class="h3">Groups to consider for BCG vaccination</span><span class="headingEndMark"> — </span>The approach to BCG vaccination policy depends on the regional prevalence of TB and is variable around the world. In countries where the prevalence of TB is moderate to high, neonatal vaccination is recommended by the WHO and is administered routinely. In some circumstances, BCG is also administered for health care workers and close contacts of patients with TB (particularly multidrug-resistant [MDR] TB) with negative tuberculin tests. In most TB-endemic countries, BCG is given to children soon after birth. Boosters are administered later in some countries despite the fact that they have been proven ineffective in adding to protection against disease. Further, they are not recommended for <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> recipients who remain negative by subsequent tuberculin testing.</p><p>In countries with a low burden of TB, universal BCG vaccination is not recommended or required. For example, routine BCG vaccination has never been implemented in the United States; instead, TB control measures have focused on detection and treatment of latent TB. Universal BCG vaccination was utilized for all school children at age 13 and all neonates in high-risk groups in the United Kingdom between 1953 and 2005. However, routine BCG vaccination was discontinued in 2005 because of diminishing incidence of TB.</p><p>The WHO does not recommend use of <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> in the countries meeting the following criteria [<a href="#rid125">125</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Average annual rate of smear-positive pulmonary TB below 5 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Average annual rate of tuberculous meningitis in children under five years below 1 per 10 million population</p><p class="bulletIndent1"><span class="glyph">●</span>Average annual risk of TB infection below 0.1 percent</p><p></p><p class="headingAnchor" id="H17"><span class="h4">Worldwide</span><span class="headingEndMark"> — </span>In settings where TB is highly endemic or where there is high risk of exposure to TB, the World Health Organization recommends that a single dose of <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> should be given to all infants [<a href="#rid125">125</a>]. BCG vaccination should be administered to healthy neonates as soon as possible after birth [<a href="#rid126">126</a>]. In addition, immunization of BCG-naïve school-age children (aged 7 to 14) not previously vaccinated has been shown to confer partial protection against TB [<a href="#rid64">64</a>].</p><p>BCG immunization practices vary by region depending on the prevalence of TB [<a href="#rid127">127-129</a>]. In countries with high prevalence of TB, childhood BCG immunization should be administered routinely. For countries with intermediate to low rates of TB (&lt;5/100,000 smear-positive cases per year), selective childhood BCG immunization for children at particular risk of TB exposure is appropriate. [<a href="#rid128">128,129</a>]. For example, BCG immunization may be reasonable for children with exposure to drug-resistant disease.</p><p>Caution in administering BCG must be exercised in regions with high prevalence of both TB and HIV. The risk of disseminated BCG in infants with HIV infection ranges from 403 to 1300 per 100,000 doses administered; in one series, a mortality rate of 75 percent was reported among children with HIV infection and disseminated BCG [<a href="#rid110">110-112</a>]. Therefore, BCG vaccination is not appropriate for infants or adults with known HIV infection (or other immunodeficiency) nor for infants with symptoms consistent with HIV infection in the absence of laboratory confirmation of actual HIV infection [<a href="#rid130">130-133</a>].</p><p>In contrast, BCG vaccination should be administered to asymptomatic infants born to mothers with unknown HIV status in countries with high TB prevalence [<a href="#rid111">111,133-135</a>]. In infants whose HIV status is unknown and who are born to HIV-positive mothers and who lack symptoms suggestive of HIV, <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> should be given after considering local factors: coverage and success of the prevention of mother to child transmission of HIV programs, possibility of deferring BCG vaccination in HIV-exposed infants until HIV infection status has been established, availability of early diagnosis of HIV infection in infants, and provision of early ART to HIV-positive infants [<a href="#rid125">125</a>].</p><p>An international advisory group has recommended that routine childhood BCG immunization be continued until all elements of an HIV testing program can be implemented [<a href="#rid111">111</a>]. Although some favor delaying BCG vaccination for HIV-exposed infants until HIV testing results are available, implementation of this approach requires careful coordination [<a href="#rid111">111</a>]. In addition, delaying <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> may reduce BCG immunization rates for children who are not HIV infected.</p><p>BCG-vaccinated infants born to mothers with HIV infection should be followed clinically to evaluate for signs of disseminated BCG. For infants with exposure to smear-positive pulmonary TB in the neonatal period, BCG vaccination should be deferred until six months of preventive INH therapy have been administered to the infant (so that INH does not inactivate the live organisms in the <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a>).</p><p class="headingAnchor" id="H18"><span class="h4">United States</span><span class="headingEndMark"> — </span>In the United States, BCG vaccination may be considered in the following circumstances [<a href="#rid136">136</a>]:</p><p class="headingAnchor" id="H4146533030"><span class="h5">Children</span><span class="headingEndMark"> — </span>BCG vaccination should only be considered for children who have a negative <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Ftb%2Ftopic%2Ftesting%2Fdefault.htm&amp;token=SH7qsgoZkYxxg8u9VLn3pbmPg%2BailgrJLc0Ue4PV4IphtlnEntk4NpKYGfQC73kYBjuKquHQSaPhzOWZgrmDNA%3D%3D&amp;TOPIC_ID=8022" target="_blank">TB test</a>, who are continually exposed, and cannot be separated from adults who:</p><p class="bulletIndent1"><span class="glyph">●</span>Are untreated or ineffectively treated for TB disease, and the child cannot be given long-term primary preventive treatment for TB infection or</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Have TB disease caused by strains resistant to <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a></p><p></p><p class="headingAnchor" id="H1852062659"><span class="h5">Health care workers</span><span class="headingEndMark"> — </span>BCG vaccination of health care workers should be considered on an individual basis in settings in which:</p><p class="bulletIndent1"><span class="glyph">●</span>A high percentage of TB patients are infected with TB strains resistant to both <a class="drug drug_general" data-topicid="8577" href="/d/drug information/8577.html" rel="external">isoniazid</a> and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is ongoing transmission of drug-resistant TB strains to health care workers and subsequent infection is likely or</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Comprehensive TB infection-control precautions have been implemented, but have not been successful</p><p></p><p class="headingAnchor" id="H19"><span class="h4">Exposure to MDR-TB</span><span class="headingEndMark"> — </span>The efficacy of BCG vaccination for health care workers, travelers, and individuals in the community with expected exposure to multidrug-resistant (MDR-) TB is uncertain. However, given the potentially significant risk of MDR-TB treatment failure, together with the relatively low rate of complications related to BCG vaccination in immunocompetent individuals, some favor administering BCG vaccination to unvaccinated, tuberculin-negative individuals exposed to MDR-TB [<a href="#rid133">133</a>]. Further study is needed to reconcile the protective efficacy of BCG vaccination in the setting of MDR-TB exposure among older children and adults.</p><p class="headingAnchor" id="H20"><span class="h5">Health care workers</span><span class="headingEndMark"> — </span>The protective efficacy of BCG vaccination in health care workers is not certain [<a href="#rid137">137</a>]. In settings with low risk of <em>M. tuberculosis</em> transmission, BCG vaccination for health care workers is not warranted [<a href="#rid137">137</a>]. In regions with high risk for TB transmission, careful adherence to TB infection control practices should be emphasized. Despite data demonstrating the limited efficacy of BCG in adults, consideration of BCG vaccination may be appropriate for health care workers from low-risk countries caring for patients or refugees in TB-endemic countries [<a href="#rid138">138,139</a>]. (See  <a class="medical medical_review" href="/d/html/8000.html" rel="external">"Tuberculosis transmission and control in health care settings"</a>.)</p><p>In the setting of substantial risk for exposure to MDR-TB strains, BCG vaccination for health care workers should be considered on an individual basis [<a href="#rid133">133</a>]. In such circumstances, counseling should be offered regarding the variable data for BCG vaccination efficacy, including discussion of risks and benefits associated with BCG vaccination.</p><p class="headingAnchor" id="H21"><span class="h3">Groups not to vaccinate</span></p><p class="headingAnchor" id="H22"><span class="h4">Immunocompromised patients</span><span class="headingEndMark"> — </span>Safety of BCG administration in immunocompromised individuals is an important concern given that it is a live vaccine. BCG vaccination should not be administered to individuals with immune compromise due to HIV infection, congenital immunodeficiency, malignancy, or immunosuppressive drugs such as corticosteroids and tumor necrosis factor-alpha blockers. (See <a class="local">'Safety and adverse effects'</a> above.)</p><p>In addition, caution should be observed among immunocompromised patients with household or other close contact with individuals recently immunized with BCG; drainage from the injection site contains live organisms and should be covered to avoid transmission.</p><p>Adults with HIV infection and individuals with HIV infection in areas of low TB prevalence should <strong>NOT</strong> receive BCG vaccination [<a href="#rid140">140</a>]. The role of BCG vaccination children with HIV infection in areas where TB is endemic is discussed in the preceding section. (See <a class="local">'Children'</a> above.)</p><p class="headingAnchor" id="H23"><span class="h4">Pregnant women</span><span class="headingEndMark"> — </span>Although BCG vaccination has not been associated with harmful fetal effects, it should not be administered in pregnancy since it is a live vaccine [<a href="#rid134">134</a>].</p><p class="headingAnchor" id="H2293709761"><span class="h3">Interpreting TST and IGRA after BCG</span><span class="headingEndMark"> — </span>Most individuals who have received <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> have a positive <a class="drug drug_general" data-topicid="10029" href="/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) two to three months following vaccination [<a href="#rid141">141</a>]. The reaction wanes with time; at more than 10 years after infant vaccination, it is generally &lt;10 mm. However, with repeated tuberculin testing, such reactions may be boosted to &gt;10 mm.</p><p class="bulletIndent1"><span class="glyph">●</span>In a study from Montreal among 5952 persons who received BCG 10 to 25 years previously, 8 percent vaccinated in infancy had significant tuberculin reactions, compared with 18 percent among those vaccinated between age 1 and 5, and 25 percent among those vaccinated after the age of 5 (p&lt;0.001) [<a href="#rid142">142</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long-term follow-up from a vaccine study among Native Americans showed that administration of BCG was associated with an increased risk of TST reactions ≥10 mm as long as 55 years later. BCG vaccination after infancy was associated with an increased risk of TST reactivity in the first 15 years after vaccination (adjusted hazard ratio [aHR] 2.33). This association remained during the interval 16 to 55 years after vaccination, although the effect was attenuated (aHR 1.26) [<a href="#rid143">143</a>].</p><p></p><p>Therefore, previous BCG vaccination may influence decisions regarding interpretation of TST results in individuals vaccinated at birth. Since interferon-gamma release assays (IGRAs) are not affected by BCG administration, this test can be used to interpret positive TSTs in persons with a history of BCG immunization or can be used as the initial test for TB infection. (See  <a class="medical medical_review" href="/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p>In the setting of serial tuberculin testing, prior BCG vaccination may be associated with boosting. The booster phenomenon is defined as a TST that is initially defined as negative (in a patient whose previous TST reactivity has diminished over time) and is then boosted to a positive test by the skin testing procedure itself. If repeated tuberculin testing is planned (such as annual screening for health care workers), initial two-step testing should be performed to distinguish tuberculin conversion from boosting. (See  <a class="medical medical_review" href="/d/html/15352.html" rel="external">"Use of interferon-gamma release assays for diagnosis of tuberculosis infection (tuberculosis screening) in adults"</a>.)</p><p>Intravesical administration of BCG for bladder cancer has been reported to result in conversion of the TST in ≥50 percent of patients but should not result in a positive IGRA [<a href="#rid144">144,145</a>].</p><p class="headingAnchor" id="H1467704225"><span class="h2">TB vaccines under development</span><span class="headingEndMark"> — </span>A major international effort is underway to develop an improved vaccine strategy for prevention of TB, an objective that is considered critical for elimination of TB by 2035. </p><p>Several candidate vaccines are in clinical trials; these include booster vaccines (designed to boost the effect of Bacille Calmette-Guérin [BCG]) and priming vaccines (intended to replace BCG) [<a href="#rid146">146,147</a>]. Types of candidate vaccines include subunit vaccines (in which antigens are delivered in a viral or other non-mycobacterial vector), live attenuated vaccines, and inactivated whole-cell vaccines [<a href="#rid148">148,149</a>]. Three designs are being used in clinical trials: Prevention of Infection (POI), Prevention of Disease (POD), and Prevention of Recurrence (POR) [<a href="#rid146">146</a>].</p><p>Two candidate vaccines have shown efficacy or proof-of-concept in phase 2 or phase 3 POD trials:</p><p class="bulletIndent1"><span class="glyph">●</span>M72/AS01E − M72/AS01E is a subunit booster vaccine consisting of two <em>M. tuberculosis </em>proteins (Mtb32A and Mtb39A) and an adjuvant (AS01E). In a randomized trial including more than 3500 HIV-uninfected adults in South Africa, Kenya, and Zambia with latent TB infection (as defined by a positive interferon-gamma release assay) and likely ongoing TB exposure, the majority of whom had received BCG vaccination as children, the incidence of TB disease was lower among those who received M72/AS01E than among those who received placebo after three years of follow-up (0.3 versus 0.6 cases per 100 person-years); the overall vaccine efficacy was 49.7 percent (95% CI 2.1-74.2) [<a href="#rid150">150,151</a>]. Protection was greater among participants ≤25 years of age than among those &gt;25 years of age, and greater among men than in women. Serious adverse events and deaths occurred with similar frequencies in the two groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>SRL-172 and DAR-901 − SRL-172 is an inactivated whole-cell booster vaccine derived from a nontuberculous mycobacterium. In a randomized phase 3 trial including more than 2000 adults with HIV in Tanzania with a history of childhood BCG randomized to receive the vaccine (five intradermal doses) or placebo, a reduction in the rate of TB disease was observed among those who received the vaccine (hazard ratio 0.61, 95% CI 0.39-0.96) [<a href="#rid152">152,153</a>]. Vaccine strain DAR-901 is a scalable manufacturing method for SRL-172 and has completed phase 1 and 2b trials [<a href="#rid154">154,155</a>].</p><p></p><p>TB vaccines are also being studied as potential therapeutic adjuncts to chemotherapy of active TB disease. </p><p class="headingAnchor" id="H1897624086"><span class="h1">NUTRITIONAL SUPPLEMENTATION</span><span class="headingEndMark"> — </span>Malnutrition is an important risk factor for TB; numerous natural history studies suggest that nutritional supplementation reduces this risk [<a href="#rid156">156-158</a>]. (See  <a class="medical medical_review" href="/d/html/8018.html" rel="external">"Epidemiology of tuberculosis", section on 'Nutritional status'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Macronutrient supplementation</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Household contacts</strong> – Nutritional supplementation may be an important intervention to reduce the risk of TB among household contacts of patients with TB disease. </p><p></p><p class="bulletIndent2">In a cluster-randomized trial in Jharkhand, India (a region with annual TB rate of 130 per 100,000, high burden of undernutrition, and low HIV prevalence), 10,345 household contacts of patients with pulmonary TB disease were randomly assigned to a nutritional intervention group or a control group [<a href="#rid159">159</a>]. The intervention included a food basket comprising 750 kcal per day (including 23 g of protein) plus micronutrients per adult, and half that amount for children &lt;10 years of age. During two years of follow-up, fewer cases of microbiologically diagnosed TB (the majority based on a positive sputum smear) were observed among the intervention group (96 versus 122 incident cases, or 1.7 versus 2.1 percent); this represented a protective efficacy of 39 percent (adjusted incidence rate ratio 0.61, 95% CI 0.43–0.85); there were no adverse effects. The individuals who referred participants for TB evaluation were not blinded to randomization assignment.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General population – </strong>Experience from natural history studies support general use of macronutrient supplementation to reduce the risk of TB in malnourished populations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Micronutrient supplementation </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin D</strong> – Vitamin D supplementation has been proposed as an intervention to reduce the risk of acquiring TBI in regions where deficiency is prevalent, but has never been demonstrated to reduce the risk of TB [<a href="#rid160">160-164</a>]. However, individuals with severe undernutrition often have numerous deficiencies; providing supplementation to address only one deficiency may be insufficient to restore the immune response [<a href="#rid165">165</a>].</p><p></p><p class="bulletIndent2">In a randomized trial including more than 8800 children in Mongolia with negative baseline QuantiFERON-TB Gold In-Tube assay (QFT) and low vitamin D levels, a weekly oral dose of 14,000 international units of <a class="drug drug_general" data-topicid="10117" href="/d/drug information/10117.html" rel="external">vitamin D3</a> over three years was not associated with reduced risk of TBI or TB disease compared with placebo [<a href="#rid166">166</a>]. Similar proportions with positive QFT in the treatment and placebo groups were observed (3.6 and 3.3 percent, respectively), and TB disease was diagnosed in 21 and 25 children, respectively. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Vitamin A</strong> – Vitamin A deficiency and low plasma retinol levels have been associated with TB disease [<a href="#rid167">167-169</a>]; it is uncertain whether this is a cause or an effect. However, trans retinoic acid, the major metabolite of vitamin A, has been shown <em>in vitro</em> and <em>in vivo</em> capable of modulating both innate and adaptive immune response elements to infection that may favor the host. Based on these studies, retinoic acid has been proposed for investigation as supplemental therapy in patients with tuberculosis [<a href="#rid170">170,171</a>].</p><p></p><p class="headingAnchor" id="H24"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preventive tools</strong> – Tools for prevention of tuberculosis (TB) include (see <a class="local">'Introduction'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nutrition supplementation</p><p class="bulletIndent2"><span class="glyph">•</span>BCG immunization</p><p class="bulletIndent2"><span class="glyph">•</span>Infection control </p><p class="bulletIndent2"><span class="glyph">•</span>Screening and treatment of TB infection (latent TB) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bacille Calmette-Guérin (BCG) is a live strain of <em>Mycobacterium bovis</em> developed by Calmette and Guérin for use as an attenuated vaccine (intradermal or multiple percutaneous puncture) to prevent tuberculosis (TB) and other mycobacterial infections. The magnitude of protection appears to be in the range of 70 to 80 percent in the first 15 years of life but falls to the range of 50 percent or lower subsequently. (See <a class="local">'Mycobacteria and host immunity'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BCG protects against pulmonary TB and is also highly effective in preventing tuberculous meningitis and disseminated disease in children. Vaccination of mycobacteria-naïve newborns and infants appears to confer greater benefit than vaccination of older children and adults who have often had other mycobacteria exposure. (See <a class="local">'Efficacy against TB disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Injection site reactions are common following BCG vaccination. Management of local reactions consists of attentive wound care, and indolent lesions are typically resolve with observation alone. Since viable organisms can be recovered from ulcer drainage, vaccination sites should be covered to reduce transmission of the vaccine strain. (See <a class="local">'Safety and adverse effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serious adverse effects of BCG include osteitis, osteomyelitis, and disseminated infection. Disseminated BCG infection following BCG vaccination occurs most commonly in the setting of HIV infection and other forms of immunosuppression. (See <a class="local">'Safety and adverse effects'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Most individuals who have received <a class="drug drug_general" data-topicid="102736" href="/d/drug information/102736.html" rel="external">BCG vaccine</a> have a tuberculin reaction of 3 to 19 mm in size at two to three months following vaccination. The reaction wanes with time; at more than 10 years after vaccination, it is generally &lt;10 mm. Testing with an interferon-gamma release assay may permit distinction between positive tuberculin reactions due to BCG versus TB. (See <a class="local">'Interpreting TST and IGRA after BCG'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In areas where the prevalence of TB is high, we recommend that a single dose of BCG be administered to healthy neonates as soon as possible after birth (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). This includes administration of BCG to neonates born to mothers with unknown HIV status. (See <a class="local">'Worldwide'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>BCG should NOT be administered to individuals with immune compromise due to HIV infection, congenital immunodeficiency, malignancy, or immunosuppressive drugs. For asymptomatic infants with unknown HIV status born to mothers known to be HIV infected, the optimal approach to BCG vaccination is uncertain and should be considered in conjunction with local factors. (See <a class="local">'Immunocompromised patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest NOT administering BCG in the setting of pregnancy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Groups not to vaccinate'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>TB vaccines under development</strong> – TB vaccines under development are discussed above. (See <a class="local">'TB vaccines under development'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nutrition supplementation</strong> – Nutritional supplementation may reduce the risk of incident TB among household contacts of patients with pulmonary TB disease. Individuals with severe undernutrition often have numerous deficiencies; providing supplementation to address only one deficiency may be insufficient to restore the immune response. (See <a class="local">'Nutritional supplementation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Behr MA, Kaufmann E, Duffin J, et al. Latent Tuberculosis: Two Centuries of Confusion. Am J Respir Crit Care Med 2021; 204:142.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Vuola JM. New vaccines for the prevention of tuberculosis. Clin Infect Dis 2002; 35:465.</a></li><li><a class="nounderline abstract_t">Edwards LB, Palmer CE. Biology of the mycobacterioses. Identification of the tuberculous-infected by skin tests. Ann N Y Acad Sci 1968; 154:140.</a></li><li><a class="nounderline abstract_t">Fine PE. Variation in protection by BCG: implications of and for heterologous immunity. Lancet 1995; 346:1339.</a></li><li><a class="nounderline abstract_t">Andrews JR, Noubary F, Walensky RP, et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 2012; 54:784.</a></li><li><a class="nounderline abstract_t">Flahiff EW. The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reactions. Am Jour Hyg 1939; 30:69.</a></li><li><a class="nounderline abstract_t">Bjartveit K. Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis. Int J Tuberc Lung Dis 2003; 7:306.</a></li><li><a class="nounderline abstract_t">HEIMBECK J. BCG vaccination of nurses. Tubercle 1948; 29:84.</a></li><li><a class="nounderline abstract_t">Verver S, Warren RM, Beyers N, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171:1430.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Horsburgh CR. Reinfection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006; 173:133.</a></li><li><a class="nounderline abstract_t">Lahey T, Mackenzie T, Arbeit RD, et al. Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. Clin Infect Dis 2013; 56:151.</a></li><li><a class="nounderline abstract_t">Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013; 368:745.</a></li><li><a class="nounderline abstract_t">Foster M, Hill PC, Setiabudiawan TP, et al. BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines. Immunol Rev 2021; 301:122.</a></li><li><a class="nounderline abstract_t">Manjaly Thomas ZR, McShane H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg 2015; 109:175.</a></li><li><a class="nounderline abstract_t">Darrah PA, Zeppa JJ, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature 2020; 577:95.</a></li><li class="breakAll">Fine PE, Carneiro IA, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programs: a discussion document. Geneva, Switzerland: Department of Vaccines and Biologicals, World Health Organization 1999. p.1.</li><li><a class="nounderline abstract_t">Soares AP, Kwong Chung CK, Choice T, et al. Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis 2013; 207:1084.</a></li><li><a class="nounderline abstract_t">Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182:1073.</a></li><li><a class="nounderline abstract_t">Mawa PA, Nkurunungi G, Egesa M, et al. The impact of maternal infection with Mycobacterium tuberculosis on the infant response to bacille Calmette-Guérin immunization. Philos Trans R Soc Lond B Biol Sci 2015; 370.</a></li><li><a class="nounderline abstract_t">Jones CE, Hesseling AC, Tena-Coki NG, et al. The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination. AIDS 2015; 29:155.</a></li><li><a class="nounderline abstract_t">Hesseling AC, Jaspan HB, Black GF, et al. Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination. Int J Tuberc Lung Dis 2015; 19:454.</a></li><li><a class="nounderline abstract_t">Boer MC, Prins C, van Meijgaarden KE, et al. Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Clin Vaccine Immunol 2015; 22:778.</a></li><li><a class="nounderline abstract_t">Tanner R, Villarreal-Ramos B, Vordermeier HM, McShane H. The Humoral Immune Response to BCG Vaccination. Front Immunol 2019; 10:1317.</a></li><li><a class="nounderline abstract_t">Kagina BM, Abel B, Bowmaker M, et al. Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response. Vaccine 2009; 27:5488.</a></li><li><a class="nounderline abstract_t">Burl S, Adetifa UJ, Cox M, et al. Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age. J Immunol 2010; 185:2620.</a></li><li><a class="nounderline abstract_t">Tchakoute CT, Hesseling AC, Kidzeru EB, et al. Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants. J Infect Dis 2015; 211:338.</a></li><li><a class="nounderline abstract_t">Kay AW, Blish CA. Delayed BCG vaccination--time to take a shot. J Infect Dis 2015; 211:335.</a></li><li><a class="nounderline abstract_t">Roy P, Vekemans J, Clark A, et al. Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. Lancet Glob Health 2019; 7:e1655.</a></li><li><a class="nounderline abstract_t">Soysal A, Millington KA, Bakir M, et al. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 2005; 366:1443.</a></li><li><a class="nounderline abstract_t">Eisenhut M, Paranjothy S, Abubakar I, et al. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine 2009; 27:6116.</a></li><li><a class="nounderline abstract_t">Chan PC, Yang CH, Chang LY, et al. Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax 2013; 68:263.</a></li><li><a class="nounderline abstract_t">Roy A, Eisenhut M, Harris RJ, et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 2014; 349:g4643.</a></li><li><a class="nounderline abstract_t">Michelsen SW, Soborg B, Koch A, et al. The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland. Thorax 2014; 69:851.</a></li><li><a class="nounderline abstract_t">Katelaris AL, Jackson C, Southern J, et al. Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort. J Infect Dis 2020; 221:146.</a></li><li><a class="nounderline abstract_t">Verrall AJ, Alisjahbana B, Apriani L, et al. Early Clearance of Mycobacterium tuberculosis: The INFECT Case Contact Cohort Study in Indonesia. J Infect Dis 2020; 221:1351.</a></li><li><a class="nounderline abstract_t">Trollfors B, Sigurdsson V, Dahlgren-Aronsson A. Prevalence of Latent TB and Effectiveness of BCG Vaccination Against Latent Tuberculosis: An Observational Study. Int J Infect Dis 2021; 109:279.</a></li><li><a class="nounderline abstract_t">Nemes E, Geldenhuys H, Rozot V, et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med 2018; 379:138.</a></li><li><a class="nounderline abstract_t">von Reyn CF. Correcting the record on BCG before we license new vaccines against tuberculosis. J R Soc Med 2017; 110:428.</a></li><li><a class="nounderline abstract_t">Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 1994; 271:698.</a></li><li><a class="nounderline abstract_t">Clemens JD, Chuong JJ, Feinstein AR. The BCG controversy. A methodological and statistical reappraisal. JAMA 1983; 249:2362.</a></li><li><a class="nounderline abstract_t">Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96:29.</a></li><li><a class="nounderline abstract_t">Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22:1154.</a></li><li><a class="nounderline abstract_t">ARONSON JD. Protective vaccination against tuberculosis with special reference to BCG vaccination. Am Rev Tuberc 1948; 58:255.</a></li><li><a class="nounderline abstract_t">FERGUSON RG, SIMES AB. BCG vaccination of Indian infants in Saskatchewan. Tubercle 1949; 30:5.</a></li><li><a class="nounderline abstract_t">ROSENTHAL SR, LOEWINSOHN E, GRAHAM ML, et al. BCG vaccination in tuberculous households. Am Rev Respir Dis 1961; 84:690.</a></li><li><a class="nounderline abstract_t">ROSENTHAL SR, LOEWINSOHNE, GRAHAM ML, et al. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics 1961; 28:622.</a></li><li><a class="nounderline abstract_t">LEVINE MI, SACKETT MF. Results of BCG immunization in New York City. Am Rev Tuberc 1946; 53:517.</a></li><li><a class="nounderline abstract_t">Aronson NE, Santosham M, Comstock GW, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA 2004; 291:2086.</a></li><li><a class="nounderline abstract_t">Hart PD, Sutherland I. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. Br Med J 1977; 2:293.</a></li><li><a class="nounderline abstract_t">Nguipdop-Djomo P, Heldal E, Rodrigues LC, et al. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis 2016; 16:219.</a></li><li><a class="nounderline abstract_t">Mangtani P, Nguipdop-Djomo P, Keogh RH, et al. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK. Health Technol Assess 2017; 21:1.</a></li><li><a class="nounderline abstract_t">Black GF, Weir RE, Floyd S, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet 2002; 359:1393.</a></li><li><a class="nounderline abstract_t">Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin Infect Dis 1995; 20:982.</a></li><li><a class="nounderline abstract_t">Hoft DF. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 2008; 372:164.</a></li><li><a class="nounderline abstract_t">Brandt L, Feino Cunha J, Weinreich Olsen A, et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 2002; 70:672.</a></li><li><a class="nounderline abstract_t">Baily GV. Tuberculosis prevention Trial, Madras. Indian J Med Res 1980; 72 Suppl:1.</a></li><li class="breakAll">Tripathy SP. Fifteen year follow-up of the Indian BCG prevention trial. In: International Union Against Tuberculosis. Singapore: Professional Postgraduate Services KK, 1986.</li><li><a class="nounderline abstract_t">Martinez L, Cords O, Liu Q, et al. Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis. Lancet Glob Health 2022; 10:e1307.</a></li><li><a class="nounderline abstract_t">Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2014; 58:470.</a></li><li><a class="nounderline abstract_t">von Reyn CF. BCG, Latitude, and Environmental Mycobacteria. Clin Infect Dis 2014; 59:607.</a></li><li><a class="nounderline abstract_t">Fordham von Reyn C, Arbeit RD, Tosteson AN, et al. The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group. AIDS 1996; 10:1025.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr, Hanson DL, Jones JL, Thompson SE 3rd. Protection from Mycobacterium avium complex disease in human immunodeficiency virus-infected persons with a history of tuberculosis. J Infect Dis 1996; 174:1212.</a></li><li><a class="nounderline abstract_t">Narayanan PR. Influence of sex, age &amp; nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India. Indian J Med Res 2006; 123:119.</a></li><li><a class="nounderline abstract_t">Pereira SM, Barreto ML, Pilger D, et al. Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial. Lancet Infect Dis 2012; 12:300.</a></li><li><a class="nounderline abstract_t">Bannister S, Sudbury E, Villanueva P, et al. The safety of BCG revaccination: A systematic review. Vaccine 2021; 39:2736.</a></li><li><a class="nounderline abstract_t">Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group. Lancet 1996; 348:17.</a></li><li><a class="nounderline abstract_t">Rodrigues LC, Pereira SM, Cunha SS, et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005; 366:1290.</a></li><li><a class="nounderline abstract_t">Glynn JR, Dube A, Fielding K, et al. The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi. Lancet Infect Dis 2021; 21:1590.</a></li><li><a class="nounderline abstract_t">Zimmermann P, Finn A, Curtis N. Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis. J Infect Dis 2018; 218:679.</a></li><li><a class="nounderline abstract_t">Behr MA, Small PM. Has BCG attenuated to impotence? Nature 1997; 389:133.</a></li><li><a class="nounderline abstract_t">Merle CS, Cunha SS, Rodrigues LC. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev Vaccines 2010; 9:209.</a></li><li><a class="nounderline abstract_t">Pittet LF, Tebruegge M, Dutta B, et al. Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine. Vaccine 2021; 39:652.</a></li><li><a class="nounderline abstract_t">Smith PG, Revill WD, Lukwago E, Rykushin YP. The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg 1976; 70:449.</a></li><li><a class="nounderline abstract_t">Muhi S, Stinear TP. Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis. Vaccine 2021; 39:7238.</a></li><li><a class="nounderline abstract_t">Portaels F, Aguiar J, Debacker M, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun 2004; 72:62.</a></li><li><a class="nounderline abstract_t">Phillips RO, Phanzu DM, Beissner M, et al. Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo. PLoS Negl Trop Dis 2015; 9:e3457.</a></li><li><a class="nounderline abstract_t">Katila ML, Brander E, Backman A. Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood. Tubercle 1987; 68:291.</a></li><li><a class="nounderline abstract_t">Romanus V, Hallander HO, Wåhlén P, et al. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis 1995; 76:300.</a></li><li><a class="nounderline abstract_t">Kontturi A, Soini H, Ollgren J, Salo E. Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016. Clin Infect Dis 2018; 67:1256.</a></li><li><a class="nounderline abstract_t">Aaby P, Roth A, Ravn H, et al. Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204:245.</a></li><li><a class="nounderline abstract_t">de Castro MJ, Pardo-Seco J, Martinón-Torres F. Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis. Clin Infect Dis 2015; 60:1611.</a></li><li><a class="nounderline abstract_t">Biering-Sørensen S, Aaby P, Lund N, et al. Early BCG-Denmark and Neonatal Mortality Among Infants Weighing &lt;2500 g: A Randomized Controlled Trial. Clin Infect Dis 2017; 65:1183.</a></li><li><a class="nounderline abstract_t">Schaltz-Buchholzer F, Bjerregaard-Andersen M, Øland CB, et al. Early Vaccination With Bacille Calmette-Guérin-Denmark or BCG-Japan Versus BCG-Russia to Healthy Newborns in Guinea-Bissau: A Randomized Controlled Trial. Clin Infect Dis 2020; 71:1883.</a></li><li><a class="nounderline abstract_t">Storgaard L, Rodrigues A, Martins C, et al. Development of BCG Scar and Subsequent Morbidity and Mortality in Rural Guinea-Bissau. Clin Infect Dis 2015; 61:950.</a></li><li><a class="nounderline abstract_t">Biering-Sørensen S, Jensen KJ, Monterio I, et al. Rapid Protective Effects of Early BCG on Neonatal Mortality Among Low Birth Weight Boys: Observations From Randomized Trials. J Infect Dis 2018; 217:759.</a></li><li><a class="nounderline abstract_t">Badurdeen S, Marshall A, Daish H, et al. Safety and Immunogenicity of Early Bacillus Calmette-Guérin Vaccination in Infants Who Are Preterm and/or Have Low Birth Weights: A Systematic Review and Meta-analysis. JAMA Pediatr 2019; 173:75.</a></li><li><a class="nounderline abstract_t">Prentice S, Nassanga B, Webb EL, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis 2021; 21:993.</a></li><li><a class="nounderline abstract_t">Pittet LF, Messina NL, Orsini F, et al. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers. N Engl J Med 2023; 388:1582.</a></li><li><a class="nounderline abstract_t">Upton CM, van Wijk RC, Mockeliunas L, et al. Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial. EClinicalMedicine 2022; 48:101414.</a></li><li><a class="nounderline abstract_t">Giamarellos-Bourboulis EJ, Tsilika M, Moorlag S, et al. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell 2020; 183:315.</a></li><li><a class="nounderline abstract_t">Faustman DL, Lee A, Hostetter ER, et al. Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Rep Med 2022; 3:100728.</a></li><li><a class="nounderline abstract_t">Snider DE, Comstock GW, Martinez I, Caras GJ. Efficacy of BCG vaccination in prevention of cancer: an update. J Natl Cancer Inst 1978; 60:785.</a></li><li><a class="nounderline abstract_t">Kendrick MA, Comstock GW. BCG vaccination and the subsequent development of cancer in humans. J Natl Cancer Inst 1981; 66:431.</a></li><li><a class="nounderline abstract_t">Skegg DC. BCG vaccination and the incidence of lymphomas and leukaemia. Int J Cancer 1978; 21:18.</a></li><li><a class="nounderline abstract_t">Comstock GW. Leukaemia and B.C.G. A controlled trial. Lancet 1971; 2:1062.</a></li><li><a class="nounderline abstract_t">Davignon L, Robillard P, Lemonde P, Frappier A. B.C.G. vaccination and leukemia mortality. Lancet 1970; 2:638.</a></li><li><a class="nounderline abstract_t">Kinlen LJ, Pike MC. B.C.G. vaccination and leukaemia. Evidence of vital statistics. Lancet 1971; 2:398.</a></li><li><a class="nounderline abstract_t">Usher NT, Chang S, Howard RS, et al. Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial. JAMA Netw Open 2019; 2:e1912014.</a></li><li><a class="nounderline abstract_t">Turnbull FM, McIntyre PB, Achat HM, et al. National study of adverse reactions after vaccination with bacille Calmette-Guérin. Clin Infect Dis 2002; 34:447.</a></li><li><a class="nounderline abstract_t">Kröger L, Korppi M, Brander E, et al. Osteitis caused by bacille Calmette-Guérin vaccination: a retrospective analysis of 222 cases. J Infect Dis 1995; 172:574.</a></li><li><a class="nounderline abstract_t">Brewer MA, Edwards KM, Palmer PS, Hinson HP. Bacille Calmette-Guérin immunization in normal healthy adults. J Infect Dis 1994; 170:476.</a></li><li><a class="nounderline abstract_t">Caglayan S, Yegin O, Kayran K, et al. Is medical therapy effective for regional lymphadenitis following BCG vaccination? Am J Dis Child 1987; 141:1213.</a></li><li><a class="nounderline abstract_t">Goraya JS, Virdi VS. Treatment of Calmette-Guérin bacillus adenitis: a metaanalysis. Pediatr Infect Dis J 2001; 20:632.</a></li><li><a class="nounderline abstract_t">Grange JM. Complications of bacille Calmette-Guérin (BCG) vaccination and immunotherapy and their management. Commun Dis Public Health 1998; 1:84.</a></li><li><a class="nounderline abstract_t">Cuello-García CA, Pérez-Gaxiola G, Jiménez Gutiérrez C. Treating BCG-induced disease in children. Cochrane Database Syst Rev 2013; :CD008300.</a></li><li><a class="nounderline abstract_t">Huang CY, Chiu NC, Chi H, et al. Clinical Manifestations, Management, and Outcomes of Osteitis/Osteomyelitis Caused by Mycobacterium bovis Bacillus Calmette-Guérin in Children: Comparison by Site(s) of Affected Bones. J Pediatr 2019; 207:97.</a></li><li><a class="nounderline abstract_t">Pöyhönen L, Nuolivirta K, Vuononvirta J, et al. Toll-like receptor 2 subfamily gene polymorphisms are associated with Bacillus Calmette-Guérin osteitis following newborn vaccination. Acta Paediatr 2015; 104:485.</a></li><li><a class="nounderline abstract_t">Segal S, Pollard AJ, Watts C, et al. Osteomyelitis of the humerus complicating BCG vaccination. Arch Dis Child 2006; 91:244.</a></li><li><a class="nounderline abstract_t">von Reyn CF. Routine childhood bacille Calmette Guérin immunization and HIV infection. Clin Infect Dis 2006; 42:559.</a></li><li><a class="nounderline abstract_t">Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guérin disease after vaccination: case report and review. Clin Infect Dis 1997; 24:1139.</a></li><li><a class="nounderline abstract_t">Hesseling AC, Cotton MF, Fordham von Reyn C, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12:1376.</a></li><li><a class="nounderline abstract_t">Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006; 42:548.</a></li><li><a class="nounderline abstract_t">Ninane J, Grymonprez A, Burtonboy G, et al. Disseminated BCG in HIV infection. Arch Dis Child 1988; 63:1268.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control (CDC). Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1985; 34:227.</a></li><li><a class="nounderline abstract_t">Lumb R, Shaw D. Mycobacterium bovis (BCG) vaccination. Progressive disease in a patient asymptomatically infected with the human immunodeficiency virus. Med J Aust 1992; 156:286.</a></li><li><a class="nounderline abstract_t">Wells CL, Jechorek RP, Twiggs LB, Brooker DC. Recovery of viable bacteria from pelvic lymph nodes of patients with gynecologic tumors. J Infect Dis 1990; 162:1216.</a></li><li><a class="nounderline abstract_t">Boudes P, Sobel A, Deforges L, Leblic E. Disseminated Mycobacterium bovis infection from BCG vaccination and HIV infection. JAMA 1989; 262:2386.</a></li><li><a class="nounderline abstract_t">Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis 2008; 12:e99.</a></li><li><a class="nounderline abstract_t">Puthanakit T, Oberdorfer P, Punjaisee S, et al. Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis 2005; 41:1049.</a></li><li><a class="nounderline abstract_t">Hong DN, Huyen MN, Lan NT, et al. Rifampin-resistant Mycobacterium bovis BCG-induced disease in HIV-infected infant, Vietnam. Emerg Infect Dis 2013; 19:1168.</a></li><li><a class="nounderline abstract_t">Hesseling AC, Schaaf HS, Hanekom WA, et al. Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children. Clin Infect Dis 2003; 37:1226.</a></li><li class="breakAll">Merck. BCG VACCINE. https://www.merck.com/product/usa/pi_circulars/b/bcg_vaccine/bcg_pi.pdf (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Hawkridge A, Hatherill M, Little F, et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 2008; 337:a2052.</a></li><li><a class="nounderline abstract_t">Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis 1996; 174:113.</a></li><li class="breakAll">World Health Organization. Guidance on how to prioritize globally constrained BCG vaccine supply to countries. https://www.who.int/immunization/diseases/tuberculosis/BCG-country-prioritization.pdf (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Lutwama F, Kagina BM, Wajja A, et al. Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants. J Infect Dis 2014; 209:887.</a></li><li><a class="nounderline abstract_t">Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease. Tuber Lung Dis 1994; 75:179.</a></li><li><a class="nounderline abstract_t">Hersh AL, Tala-Heikkilä M, Tala E, et al. A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland. Int J Tuberc Lung Dis 2003; 7:22.</a></li><li><a class="nounderline abstract_t">Fine P. Stopping routine vaccination for tuberculosis in schools. BMJ 2005; 331:647.</a></li><li><a class="nounderline abstract_t">O'Brien KL, Ruff AJ, Louis MA, et al. Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature. Pediatrics 1995; 95:414.</a></li><li><a class="nounderline abstract_t">Muram D. Labial adhesions in sexually abused children. JAMA 1988; 259:352.</a></li><li><a class="nounderline abstract_t">Lallemant-Le Coeur S, Lallemant M, Cheynier D, et al. Bacillus Calmette-Guérin immunization in infants born to HIV-1-seropositive mothers. AIDS 1991; 5:195.</a></li><li class="breakAll">WHO Weekly Epidemiological Record 25 May 2007. http://www.who.int/wer/2007/wer8221.pdf?ua=1 (Accessed on July 20, 2018).</li><li><a class="nounderline abstract_t">The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45:1.</a></li><li><a class="nounderline abstract_t">Felten MK, Leichsenring M. Use of BCG in high prevalence areas for HIV. Trop Med Parasitol 1995; 46:69.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Vaccines. https://www.cdc.gov/tb/topic/basics/vaccines.htm (Accessed on December 06, 2021).</li><li><a class="nounderline abstract_t">Brewer TF, Colditz GA. Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in health care workers. Clin Infect Dis 1995; 20:136.</a></li><li><a class="nounderline abstract_t">Brewer TF, Heymann SJ, Krumplitsch SM, et al. Strategies to decrease tuberculosis in us homeless populations: a computer simulation model. JAMA 2001; 286:834.</a></li><li><a class="nounderline abstract_t">Cobelens FG, van Deutekom H, Draayer-Jansen IW, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000; 356:461.</a></li><li class="breakAll">WHO Weekly Epidemiological Record 23 January 2004. http://www.who.int/wer/2004/en/wer7904.pdf?ua=1 (Accessed on July 20, 2018).</li><li><a class="nounderline abstract_t">Menzies D. What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us? Clin Infect Dis 2000; 31 Suppl 3:S71.</a></li><li><a class="nounderline abstract_t">Menzies R, Vissandjee B. Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity. Am Rev Respir Dis 1992; 145:621.</a></li><li><a class="nounderline abstract_t">Mancuso JD, Mody RM, Olsen CH, et al. The Long-term Effect of Bacille Calmette-Guérin Vaccination on Tuberculin Skin Testing: A 55-Year Follow-Up Study. Chest 2017; 152:282.</a></li><li><a class="nounderline abstract_t">Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985; 134:40.</a></li><li><a class="nounderline abstract_t">Silverman MS, Reynolds D, Kavsak PA, et al. Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis. Clin Biochem 2007; 40:913.</a></li><li><a class="nounderline abstract_t">Kaufmann SH, Weiner J, von Reyn CF. Novel approaches to tuberculosis vaccine development. Int J Infect Dis 2017; 56:263.</a></li><li class="breakAll">Stop TB Partnership. TB Vaccine Pipeline. https://newtbvaccines.org/tb-vaccine-pipeline/ (Accessed on October 25, 2022).</li><li><a class="nounderline abstract_t">Hatherill M, White RG, Hawn TR. Clinical Development of New TB Vaccines: Recent Advances and Next Steps. Front Microbiol 2019; 10:3154.</a></li><li><a class="nounderline abstract_t">Schrager LK, Vekemens J, Drager N, et al. The status of tuberculosis vaccine development. Lancet Infect Dis 2020; 20:e28.</a></li><li><a class="nounderline abstract_t">Van Der Meeren O, Hatherill M, Nduba V, et al. Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med 2018; 379:1621.</a></li><li><a class="nounderline abstract_t">Tait DR, Hatherill M, Van Der Meeren O, et al. Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med 2019; 381:2429.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Mtei L, Arbeit RD, et al. Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010; 24:675.</a></li><li><a class="nounderline abstract_t">Weng H, Huang JY, Meng XY, et al. Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis. Biomed Rep 2016; 4:595.</a></li><li><a class="nounderline abstract_t">von Reyn CF, Lahey T, Arbeit RD, et al. Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901. PLoS One 2017; 12:e0175215.</a></li><li><a class="nounderline abstract_t">Munseri P, Said J, Amour M, et al. DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial. Vaccine 2020; 38:7239.</a></li><li><a class="nounderline abstract_t">Sinha P, Mehta S. Food: the tuberculosis vaccine we already have. Lancet 2023; 402:588.</a></li><li><a class="nounderline abstract_t">Sinha P, Davis J, Saag L, et al. Undernutrition and Tuberculosis: Public Health Implications. J Infect Dis 2019; 219:1356.</a></li><li><a class="nounderline abstract_t">Koethe JR, von Reyn CF. Protein-calorie malnutrition, macronutrient supplements, and tuberculosis. Int J Tuberc Lung Dis 2016; 20:857.</a></li><li><a class="nounderline abstract_t">Bhargava A, Bhargava M, Meher A, et al. Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial. Lancet 2023; 402:627.</a></li><li><a class="nounderline abstract_t">Martineau AR. Old wine in new bottles: vitamin D in the treatment and prevention of tuberculosis. Proc Nutr Soc 2012; 71:84.</a></li><li><a class="nounderline abstract_t">Ganmaa D, Khudyakov P, Buyanjargal U, et al. Prevalence and Determinants of QuantiFERON-Diagnosed Tuberculosis Infection in 9810 Mongolian Schoolchildren. Clin Infect Dis 2019; 69:813.</a></li><li><a class="nounderline abstract_t">Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007; 176:208.</a></li><li><a class="nounderline abstract_t">Ganmaa D, Giovannucci E, Bloom BR, et al. Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial. Am J Clin Nutr 2012; 96:391.</a></li><li><a class="nounderline abstract_t">Aibana O, Huang CC, Aboud S, et al. Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis. PLoS Med 2019; 16:e1002907.</a></li><li><a class="nounderline abstract_t">Sudfeld CR, Mugusi F, Muhihi A, et al. Efficacy of vitamin D3 supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2020; 7:e463.</a></li><li><a class="nounderline abstract_t">Ganmaa D, Uyanga B, Zhou X, et al. Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. N Engl J Med 2020; 383:359.</a></li><li><a class="nounderline abstract_t">Hanekom WA, Potgieter S, Hughes EJ, et al. Vitamin A status and therapy in childhood pulmonary tuberculosis. J Pediatr 1997; 131:925.</a></li><li><a class="nounderline abstract_t">Oh J, Choi R, Park HD, et al. Evaluation of vitamin status in patients with pulmonary tuberculosis. J Infect 2017; 74:272.</a></li><li><a class="nounderline abstract_t">Podell BK, Aibana O, Huang CC, et al. The Impact of Vitamin A Deficiency on Tuberculosis Progression. Clin Infect Dis 2022; 75:2178.</a></li><li><a class="nounderline abstract_t">Larange A, Cheroutre H. Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the Immune System. Annu Rev Immunol 2016; 34:369.</a></li><li><a class="nounderline abstract_t">Bahlool AZ, Grant C, Cryan SA, et al. All trans retinoic acid as a host-directed immunotherapy for tuberculosis. Curr Res Immunol 2022; 3:54.</a></li></ol></div><div id="topicVersionRevision">Topic 8022 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33761302" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Latent Tuberculosis: Two Centuries of Confusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12145732" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New vaccines for the prevention of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5266317" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Biology of the mycobacterioses. Identification of the tuberculous-infected by skin tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7475776" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Variation in protection by BCG: implications of and for heterologous immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22267721" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The occurrence of tuberculosis in persons who failed to react to tuberculin, and in persons with positive tuberculin reactions</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729334" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Olaf Scheel and Johannes Heimbeck: their contribution to understanding the pathogenesis and prevention of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18909014" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : BCG vaccination of nurses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15831840" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16368796" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reinfection with Mycobacterium tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972862" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425167" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33709421" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : BCG-induced protection against Mycobacterium tuberculosis infection: Evidence, mechanisms, and implications for next-generation vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25636950" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Aerosol immunisation for TB: matching route of vaccination to route of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31894150" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevention of tuberculosis in macaques after intravenous BCG immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31894150" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevention of tuberculosis in macaques after intravenous BCG immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23293360" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20558627" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25964450" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The impact of maternal infection with Mycobacterium tuberculosis on the infant response to bacille Calmette-Guérin immunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25535752" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The impact of HIV exposure and maternal Mycobacterium tuberculosis infection on infant immune responses to bacille Calmette-Guérin vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25860002" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunogenicity of BCG in HIV-exposed and non-exposed infants following routine birth or delayed vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25947145" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31244856" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The Humoral Immune Response to BCG Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19616494" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Delaying BCG vaccination from birth to 10 weeks of age may result in an enhanced memory CD4 T cell response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20644160" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Delaying bacillus Calmette-Guérin vaccination from birth to 4 1/2 months of age reduces postvaccination Th1 and IL-17 responses but leads to comparable mycobacterial responses at 9 months of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25108027" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Delaying BCG vaccination until 8 weeks of age results in robust BCG-specific T-cell responses in HIV-exposed infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25108029" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Delayed BCG vaccination--time to take a shot.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31708146" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243089" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19715782" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23019256" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25097193" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24969643" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effectiveness of BCG vaccination in preventing Mycobacterium tuberculosis infection and disease in Greenland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504674" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effectiveness of BCG Vaccination Against Mycobacterium tuberculosis Infection in Adults: A Cross-sectional Analysis of a UK-Based Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31298280" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Early Clearance of Mycobacterium tuberculosis: The INFECT Case Contact Cohort Study in Indonesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34174429" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prevalence of Latent TB and Effectiveness of BCG Vaccination Against Latent Tuberculosis: An Observational Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29996082" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28949270" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Correcting the record on BCG before we license new vaccines against tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8309034" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6834635" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The BCG controversy. A methodological and statistical reappraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7596718" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8144299" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18891458" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Protective vaccination against tuberculosis with special reference to BCG vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18102809" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : BCG vaccination of Indian infants in Saskatchewan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14494078" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : BCG vaccination in tuberculous households.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14494079" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20992285" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Results of BCG immunization in New York City.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126436" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/326347" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26603173" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28738015" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11978337" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795103" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18620952" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Tuberculosis vaccine development: goals, immunological design, and evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11796598" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7005086" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Tuberculosis prevention Trial, Madras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7005086" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Tuberculosis prevention Trial, Madras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35961354" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Infant BCG vaccination and risk of pulmonary and extrapulmonary tuberculosis throughout the life course: a systematic review and individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24336911" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24803373" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : BCG, Latitude, and Environmental Mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8853737" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The international epidemiology of disseminated Mycobacterium avium complex infection in AIDS. International MAC Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8940211" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Protection from Mycobacterium avium complex disease in human immunodeficiency virus-infected persons with a history of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16575109" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Influence of sex, age&amp;nontuberculous infection at intake on the efficacy of BCG: re-analysis of 15-year data from a double-blind randomized control trial in South India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071248" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effectiveness and cost-effectiveness of first BCG vaccination against tuberculosis in school-age children without previous tuberculin test (BCG-REVAC trial): a cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33810902" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The safety of BCG revaccination: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8691924" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Karonga Prevention Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16214599" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34237262" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29635431" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Does BCG Vaccination Protect Against Nontuberculous Mycobacterial Infection? A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9296487" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Has BCG attenuated to impotence?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20109030" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33371993" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Mycobacterium ulcerans-specific immune response after immunisation with bacillus Calmette-Guérin (BCG) vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/841647" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34119347" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Systematic review of M. Bovis BCG and other candidate vaccines for Buruli ulcer prophylaxis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14688081" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25569674" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Effectiveness of routine BCG vaccination on buruli ulcer disease: a case-control study in the Democratic Republic of Congo, Ghana and Togo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3138802" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579311" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29584893" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Increase in Childhood Nontuberculous Mycobacterial Infections After Bacille Calmette-Guérin Coverage Drop: A Nationwide, Population-Based Retrospective Study, Finland, 1995-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21673035" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25725054" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29579158" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Early BCG-Denmark and Neonatal Mortality Among Infants Weighing&lt;2500 g: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31677386" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Early Vaccination With Bacille Calmette-Guérin-Denmark or BCG-Japan Versus BCG-Russia to Healthy Newborns in Guinea-Bissau: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26060293" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Development of BCG Scar and Subsequent Morbidity and Mortality in Rural Guinea-Bissau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29216358" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Rapid Protective Effects of Early BCG on Neonatal Mortality Among Low Birth Weight Boys: Observations From Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476973" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Safety and Immunogenicity of Early Bacillus Calmette-Guérin Vaccination in Infants Who Are Preterm and/or Have Low Birth Weights: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33609457" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37099341" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35582122" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Safety and efficacy of BCG re-vaccination in relation to COVID-19 morbidity in healthcare workers: A double-blind, randomised, controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32941801" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36027906" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/344899" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Efficacy of BCG vaccination in prevention of cancer: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7009946" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : BCG vaccination and the subsequent development of cancer in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/624598" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : BCG vaccination and the incidence of lymphomas and leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4106914" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Leukaemia and B.C.G. A controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4195773" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : B.C.G. vaccination and leukemia mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4105174" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : B.C.G. vaccination and leukaemia. Evidence of vital statistics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31553471" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11797170" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : National study of adverse reactions after vaccination with bacille Calmette-Guérin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7622909" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Osteitis caused by bacille Calmette-Guérin vaccination: a retrospective analysis of 222 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035041" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Bacille Calmette-Guérin immunization in normal healthy adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3673975" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Is medical therapy effective for regional lymphadenitis following BCG vaccination?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419511" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Treatment of Calmette-Guérin bacillus adenitis: a metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9644119" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Complications of bacille Calmette-Guérin (BCG) vaccination and immunotherapy and their management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440826" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Treating BCG-induced disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30577978" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Clinical Manifestations, Management, and Outcomes of Osteitis/Osteomyelitis Caused by Mycobacterium bovis Bacillus Calmette-Guérin in Children: Comparison by Site(s) of Affected Bones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605403" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Toll-like receptor 2 subfamily gene polymorphisms are associated with Bacillus Calmette-Guérin osteitis following newborn vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16492888" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Osteomyelitis of the humerus complicating BCG vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421801" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Routine childhood bacille Calmette Guérin immunization and HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9195072" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Disseminated bacille Calmette-Guérin disease after vaccination: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017445" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421800" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3196057" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Disseminated BCG in HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3920493" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Disseminated Mycobacterium bovis infection from BCG vaccination of a patient with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1738331" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Mycobacterium bovis (BCG) vaccination. Progressive disease in a patient asymptomatically infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2230252" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Recovery of viable bacteria from pelvic lymph nodes of patients with gynecologic tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2677428" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Disseminated Mycobacterium bovis infection from BCG vaccination and HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18799339" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16142674" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23764043" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Rifampin-resistant Mycobacterium bovis BCG-induced disease in HIV-infected infant, Vietnam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557968" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557968" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19008268" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8655980" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8655980" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24179111" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Distinct T-cell responses when BCG vaccination is delayed from birth to 6 weeks of age in Ugandan infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7919307" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Criteria for discontinuation of vaccination programmes using Bacille Calmette-Guerin (BCG) in countries with a low prevalence of tuberculosis. A statement of the International Union Against Tuberculosis and Lung Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12701831" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16179677" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Stopping routine vaccination for tuberculosis in schools.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7862483" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Bacillus Calmette-Guérin complications in children born to HIV-1-infected women with a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336153" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Labial adhesions in sexually abused children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2031692" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Bacillus Calmette-Guérin immunization in infants born to HIV-1-seropositive mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2031692" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Bacillus Calmette-Guérin immunization in infants born to HIV-1-seropositive mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8602127" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8525287" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Use of BCG in high prevalence areas for HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8525287" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Use of BCG in high prevalence areas for HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7727639" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Bacille Calmette-Guérin vaccination for the prevention of tuberculosis in health care workers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11497538" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Strategies to decrease tuberculosis in us homeless populations: a computer simulation model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10981889" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10981889" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11010826" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : What does tuberculin reactivity after bacille Calmette-Guérin vaccination tell us?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1546843" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Effect of bacille Calmette-Guérin vaccination on tuberculin reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28087302" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : The Long-term Effect of Bacille Calmette-Guérin Vaccination on Tuberculin Skin Testing: A 55-Year Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3892050" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Bacillus Calmette-Guerin immunotherapy for bladder cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17512514" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816661" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Novel approaches to tuberculosis vaccine development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27816661" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Novel approaches to tuberculosis vaccine development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32082273" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Clinical Development of New TB Vaccines: Recent Advances and Next Steps.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32014117" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : The status of tuberculosis vaccine development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30280651" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31661198" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20118767" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Prevention of tuberculosis in Bacille Calmette-Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27123253" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Adjunctive therapy of Mycobacterium vaccae vaccine in the treatment of multidrug-resistant tuberculosis: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28498853" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33004239" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : DAR-901 vaccine for the prevention of infection with Mycobacterium tuberculosis among BCG-immunized adolescents in Tanzania: A randomized controlled, double-blind phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37567199" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Food: the tuberculosis vaccine we already have.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476125" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Undernutrition and Tuberculosis: Public Health Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27287634" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Protein-calorie malnutrition, macronutrient supplements, and tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37567200" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Nutritional supplementation to prevent tuberculosis incidence in household contacts of patients with pulmonary tuberculosis in India (RATIONS): a field-based, open-label, cluster-randomised, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123447" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Old wine in new bottles: vitamin D in the treatment and prevention of tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30481273" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Prevalence and Determinants of QuantiFERON-Diagnosed Tuberculosis Infection in 9810 Mongolian Schoolchildren.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17463418" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : A single dose of vitamin D enhances immunity to mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22760564" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Vitamin D, tuberculin skin test conversion, and latent tuberculosis in Mongolian school-age children: a randomized, double-blind, placebo-controlled feasibility trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509529" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32621874" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Efficacy of vitamin D3 supplementation for the prevention of pulmonary tuberculosis and mortality in HIV: a randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32706534" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427903" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Vitamin A status and therapy in childhood pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27838523" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Evaluation of vitamin status in patients with pulmonary tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35486953" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : The Impact of Vitamin A Deficiency on Tuberculosis Progression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27168242" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Retinoic Acid and Retinoic Acid Receptors as Pleiotropic Modulators of the Immune System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35496824" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : All trans retinoic acid as a host-directed immunotherapy for tuberculosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
